Skip to content
MatchScript
Menu

Evidence review

Semaglutide vs Tirzepatide: Which One Is Right for You

Semaglutide and tirzepatide compared on average results, tolerability, and cost — a measured guide to which molecule fits your goals.

By The MatchScript Team, Matching & Recommendations Desk

Semaglutide and tirzepatide are the two GLP-1 medications almost everyone is choosing between. They're related but not identical, and the "better" one really depends on your goals, your tolerance for side effects, and your budget. Here's a measured comparison to help you find your fit. Any prices mentioned reflect each provider's published pricing (last reviewed 2026).

The quick version Both are once-weekly injections that curb appetite and slow gastric emptying. Semaglutide (the molecule in Wegovy) acts on the GLP-1 receptor[[cite:4]]. Tirzepatide (the molecule in Zepbound) acts on two receptors — GLP-1 and GIP[[cite:5]] — which is part of why its average results in trials ran higher.

What the trials showed In the STEP-1 trial, once-weekly semaglutide produced about 15% average body-weight loss over 68 weeks in adults with overweight or obesity[[cite:1]]. In SURMOUNT-1, tirzepatide reached roughly the low-to-mid 20% range at its higher doses over 72 weeks[[cite:2]]. A head-to-head trial in people with type 2 diabetes, SURPASS-2, compared the two directly and found tirzepatide led to greater reductions in A1C and body weight than semaglutide[[cite:3]]. So on averages, tirzepatide tends to come out ahead — but averages aren't individuals.

Why the higher average isn't the whole story Trial averages describe groups, not you. Plenty of people reach their goals on semaglutide, and it has a longer real-world track record. Tolerability also varies person to person — both can cause nausea, and the right dose and a slow titration often matter more than which molecule you pick. If side effects are your main worry, that's a conversation for your provider, not a reason to assume one is universally gentler.

Cost and access Semaglutide is frequently the lower-cost option, especially in compounded form, and it's widely available across providers. Tirzepatide often costs more but appeals to people prioritizing the highest average results. If cost is shaping your decision, our [compounded vs brand-name](/compounded-vs-brand-name-glp1) guide explains the price gap, and the [comparison hub](/compare) lines up each provider's semaglutide and tirzepatide pricing side by side.

Which fits you Choose semaglutide if you want a proven, widely available, usually lower-cost option and are comfortable with strong-but-slightly-lower average results. Lean tirzepatide if you're prioritizing the highest average weight loss and the cost works for you. Either way, decide the delivery format too — see [injections vs oral or sublingual](/injections-vs-oral-glp1) — and confirm your chosen provider offers the molecule you want.

Let the quiz match you Still torn? The [2-minute quiz](/quiz) folds molecule preference, budget, and support into our honest [Match Score](/methodology) and surfaces providers that carry your pick. You can also compare a low-cost, single-price option like [Found](/reviews/found) — which charges the same for either molecule — against others in the [comparison hub](/compare).

Frequently asked questions

Is tirzepatide always better than semaglutide?

On trial averages, tirzepatide produced greater weight loss and beat semaglutide head-to-head in a type 2 diabetes study. But averages describe groups, not individuals — many people reach their goals on semaglutide, and tolerability and cost matter too.

Which has fewer side effects?

Both can cause nausea and other GI effects, and it varies by person. A slow dose titration often matters more than the molecule. Discuss side-effect concerns with your provider rather than assuming one is universally gentler.

Which is cheaper?

Semaglutide is frequently the lower-cost option, especially compounded, while tirzepatide often costs more. Some providers charge the same for either molecule, so check pricing in the comparison hub.

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
  3. Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
  4. U.S. Food and Drug Administration (2021). FDA Approves New Drug Treatment for Chronic Weight Management (Wegovy). FDA. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
  5. U.S. Food and Drug Administration (2023). FDA Approves New Medication for Chronic Weight Management (Zepbound). FDA. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Continue reading